Related Experiment Video
Updated: Nov 23, 2025

Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques
Published on: March 13, 2015
The Enhanced Liver Fibrosis (ELF) Panel: Analyte Stability Under Common Sample Storage Conditions Used in Clinical
Oliver J Kennedy1, Julie Parkes1,2, Sudeep Tanwar2
1Primary Care & Population Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, UK.
Background:
The enhanced liver fibrosis (ELF) blood test has recently been recommended by the National Institute for Health and Care Excellence to test for advanced fibrosis in nonalcoholic fatty liver disease. The ELF test involves calculating a score from the concentrations of serum biomarkers: tissue inhibitor of matrix metalloproteinases-1 (TIMP-1), aminoterminal propeptide of procollagen type III (P3NP), and hyaluronic acid (HA). Blood samples for the ELF score are often acquired in primary care and may be stored before analysis. However, the effect of preanalytical storage on the ELF test is not known.
Methods:
We conducted experiments to assess the stabilities of the ELF score, P3NP, HA, and TIMP-1 under medium- to long-term storage at -80 °C, repeated freeze-thawing, and refrigeration at 4 °C for days.
Results:
Mean TIMP-1 concentrations increased during medium- to long-term storage (+16.5%) and refrigeration (+4.9%), but were stable during freeze-thawing. Mean P3NP concentrations were stable under medium- to long-term storage, but increased during refrigeration (+7.4%) and freeze-thawing (+9.3%). Mean HA concentrations decreased during medium- to long-term storage (-12.3%) but were stable during refrigeration and freeze-thawing. Despite changes in biomarker concentrations, the changes in the mean ELF score were not clinically significant and not >0.1 U (0.7%).
Conclusions:
The ELF score was stable, with no clinically significant changes under common storage conditions. These findings demonstrate that the ELF score is robust in situations where analysis may be delayed.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Sample Handling
Samples should be transported carefully from collection points to the laboratory. They should be properly sealed and clearly labeled to prevent cross-contamination. To preserve the sample integrity, optimal temperature conditions during transport are essential. This could involve using...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

